SlideShare une entreprise Scribd logo
1  sur  25
Agents For ADHD
Brian J. Piper, Ph.D., M.S.
   piperbj@husson.edu




               February 12, 2013
Goals
• Pharmacy students should be:
  – familiar with ADHD-I, ADHD-HI, and ADHD-C
  – able to contrast the MOA, AE, and abuse potential
    of stimulant and non-stimulant
    pharmacotherapies for ADHD
History of ADHD


    • ≈1910: Minimal Brain Damage: inattentive,
      distractible, hyper/hypoactive
    • 1980: Attention Deficit Disorder: normal IQ,
      poor sustained attention, added to DSM III
    • 1994: ADD is removed from DSM IV
    • 2013: “Symptoms present by age” changed
      from 7 to 12
Taylor (2011). Attention Deficit Hyperactivity Disorder, 3, 69-75.
ADHD: Inattentive
ADHD: Hyperactive/Impulsive
AHDH Epidemiology
 •   Very common in children (6%) & adults (4%)
 •   Substantial regional variability (Maine = 9.6%)
 •   Males (4) > Females (1)
 •   Moderate genetic component in males




Visser et al. (2010) MMWR, 59(44), 1439-1433. http://www.cdc.gov/ncbddd/adhd/prevalence.html
ADHD Combined: ↓Cortical Volume




                                                       <- Controls
                                                       <- ADHD




Castellanos et al. (2002). JAMA, 288(14), 1740-1748.
Dopamine Transporter (DAT)


                                   Dopamine
•   Neuroanatomy:
     – Somas: substantia nigra
     – Axons: striatum
•   Functions: movement, mood, reward, cognition
Dopamine
•   Neuroanatomy:
     – Somas: Ventral Tegmental Area (VTA)
     – Axons: Nucleus Accumbens
•   Functions: movement, mood, reward, cognition
Dopamine
  •    Neuroanatomy:
        – Somas: Ventral Tegmental Area (VTA)
        – Axons: Prefrontal Cortex (PFC)
  •    Functions: movement, mood, reward, cognition




Modified from Meyer & Quezner (2008). Psychopharmacology.
Norepinephrine
        • Neuroanatomy
                – somas: Locus Coeruleus
                – axons: Forebrain+
        • Receptors: α1A,1B,1D, α2A,2B,2C, β1, β2, β3
        • Function: attention, cardiac




Modified from Meyer & Quezner (2008). Psychopharmacology.
Amphetamine
• History:
  – synthesized in 1883
  – benzedrine in 1933
• Indications: ADHD (age 3+ ), narcolepsy
• MOA:
  – DAT inhibition & reversal
  – NET inhibition & reversal
  – VMAT2 inhibition
  – MAO inhibition (weak)
Amphetamine Neurobehavioral Effects ≠
                   Paradoxical
•   14 Boys (age 6-12, IQ = 131) randomized to receive 5 mg/kg
    dextroamphetamine or placebo
•   Cognitive battery completed at 30 – 150 min post drug




Rapoport, J. et al. (1978). Science, 199, 563-566.
Methamphetamine
•   History: synthesized in 1893
•   Indications: ADHD, obesity
•   Metabolite: amphetamine
•   MOA:
    – DAT inhibition & reversal
    – NET inhibition & reversal
    – SERT inhibition & reversal
    – VMAT2 inhibition
    – MAO inhibition ( ? )
Methylphenidate

    • History: synthesized in 1944
    • Adverse Effects:
         – nervousness
         – ↓ appetite/weight
         – ↑blood pressure/heart rate
                                                   Leandro (& Marguerite)
    • MOA:                                               Panizzon

         – DAT/NET inhibition
         – DA/NE release (moderate)
http://www.cesar.umd.edu/cesar/drugs/ritalin.asp
Comparison (All Schedule II)
• Amphetamine (Adderall):



• Methamphetamine (Desoxyn):



• Methylphenidate (Ritalin SR):
Monitoring the Future: “Amphetamines” =
            Adderall & Ritalin
Recreational Methamphetamine &
           11
                           DAT Depletions
         [ C]d-methylphenidate




Volkow et al. (2001). Journal of Neuroscience, 21(23), 9414-9418.
Stimulants & Neurotoxicity
    • Rats received doses, chosen
      to produce 2-5X plasma
      therapeutic levels of:
         – amphetamine (AMPH)
         – methamphetamine (METH)
         – methylphenidate (MPH)
    • Animals monitored for
      hyperthermia
    • Dopamine at 1 week:
         – MPH = controls
         – ↓ METH
         – ↓ AMPH



Levi et al. (2012). Neurotoxicology & Teratology, 34, 253-262.
Diversion Proof?
              Lisdexamfetamine   Guanfacine     Atomoxetine



              DAT/NET,
MOA           D-amphetamine
                                                NRI
              prodrug            α2A agonist
              ADHD (>6 yrs),     ADHD,          ADHD
Indications                      hypertension


Scheduled     Yes, II            No             No

              Abuse potential,                  Suicidal
Warning       sudden death
                                 No             thoughts/
                                                behavior
Total estimated number of outpatient prescriptions for ADHD drug market drug products dispensed
                  to the US children (ages 0–17 years) from US retail pharmacies.




                  ---------------------------------------------------------------------------------------------------



                                                                                                                        ↓
                  --------------------------------------------------------------------------------------------------
                                                                                                                        ↑
                                                                                                                        ↑
                                                                                                                        ↓




Chai G et al. (2012). Pediatrics, 130, 23-31.
Treatment for ADHD (DiPiro)
  • “Multimodal treatment (parent training, family training,
    classroom interventions, contingency management) is
    crucial for an overall positive therapeutic outcome.”
  • Pharmacotherapies
     – 1st Line: methylphenidate or amphetamine
     – 2nd Line: atomoxetine or guanafacine or bupropion
     – 3rd Line: combine above or add tricyclic
       antidepressant



Copheide & Pliszka (2011). In DiPiro’s Pharmacotherapy: A Pathophysiological Approach, p. 1088.
Treatment for Hyperkinetic Disorder
                    (European)
    •   1st Line: Psychoeducation
    •   2nd Line: methylphenidate
    •   3rd Line: other stimulant
    •   4th Line: TCA, nicotine patch




Taylor et al. (2004). Eur Child & Adolescent Psychiatry, 13(S1), DOI 10.1007/s00787-004-1002-x
Multimodal Treatment Study of
             Children With ADHD (MTA)
 • Children (7-10 y.o.) with ADHD-C (N=579)
   randomized for 14 months to:
      – Medication Management (MM): methylphenidate (37.7
        mg/day), monthly monitoring of adverse effects (parent)
      – Behavioral Therapy (BT): summer camp (9 hours/day x 5
        weeks) + parent training + teaching aid (60 days)
      – Combined (MM & BT): methylphenidate (30.5 mg/day),
        monthly monitoring of adverse effects (parent & teacher)
      – Community Care: treatment as usual in the community (67%
        pharmacotherapy)



MTA Group (1999). Archives of Psychology, 56(12), 1073-1086.
Interpretation?
  •   1) All groups improved relative to baseline.
  •   2) Behavioral Treatment doesn’t work
  •   3) Medication Management > Other
  •   4) Behavioral Treatment = Community Care


                         --------------------------------------------------------------------




MTA Group (1999). Archives of Psychology, 56(12), 1073-1086.

Contenu connexe

Tendances

Pharmacological treatment of schizophrenia
Pharmacological treatment of schizophreniaPharmacological treatment of schizophrenia
Pharmacological treatment of schizophreniajoanna1956
 
ADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementJacob Kagan
 
Psychosis and antipsychotics (1)
Psychosis and antipsychotics (1)Psychosis and antipsychotics (1)
Psychosis and antipsychotics (1)Adonis Sfera, MD
 
Anti-psychotic Drugs or neuroleptics slides
Anti-psychotic Drugs or neuroleptics slides Anti-psychotic Drugs or neuroleptics slides
Anti-psychotic Drugs or neuroleptics slides Sadia Rukhsar
 
Atypical antipsychotics
Atypical antipsychoticsAtypical antipsychotics
Atypical antipsychoticsKarrar Husain
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophreniaGAURAVUPPAL23
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophreniaSWATI SINGH
 
Opioids dependence and management
Opioids dependence and managementOpioids dependence and management
Opioids dependence and managementBSMMU
 
Dopamine hypothesis
Dopamine hypothesisDopamine hypothesis
Dopamine hypothesiskellula
 
Psychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseasePsychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseaseSoumen Karmakar
 
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical DataVortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical DataAmit Vishwakarma
 
Antipsychotic Agents
Antipsychotic AgentsAntipsychotic Agents
Antipsychotic AgentsAkshil Mehta
 

Tendances (20)

Pharmacological treatment of schizophrenia
Pharmacological treatment of schizophreniaPharmacological treatment of schizophrenia
Pharmacological treatment of schizophrenia
 
ADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and ManagementADHD and Addiction: Diagnosis and Management
ADHD and Addiction: Diagnosis and Management
 
Psychosis and antipsychotics (1)
Psychosis and antipsychotics (1)Psychosis and antipsychotics (1)
Psychosis and antipsychotics (1)
 
ADHD in Adults
ADHD in AdultsADHD in Adults
ADHD in Adults
 
What is schizophrenia
What is schizophreniaWhat is schizophrenia
What is schizophrenia
 
Mood stabilizers
Mood stabilizersMood stabilizers
Mood stabilizers
 
Anti-psychotic Drugs or neuroleptics slides
Anti-psychotic Drugs or neuroleptics slides Anti-psychotic Drugs or neuroleptics slides
Anti-psychotic Drugs or neuroleptics slides
 
Anxiety Disorders
Anxiety DisordersAnxiety Disorders
Anxiety Disorders
 
Atypical antipsychotics
Atypical antipsychoticsAtypical antipsychotics
Atypical antipsychotics
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophrenia
 
Treatment resistant schizophrenia
Treatment resistant schizophreniaTreatment resistant schizophrenia
Treatment resistant schizophrenia
 
Opioids dependence and management
Opioids dependence and managementOpioids dependence and management
Opioids dependence and management
 
Dopamine hypothesis
Dopamine hypothesisDopamine hypothesis
Dopamine hypothesis
 
Anti psychotic drugs
Anti psychotic drugsAnti psychotic drugs
Anti psychotic drugs
 
Psychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's DiseasePsychiatric manifestations of Parkinson's Disease
Psychiatric manifestations of Parkinson's Disease
 
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical DataVortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
 
Pharmacotherapy of Schizophrenia
Pharmacotherapy of SchizophreniaPharmacotherapy of Schizophrenia
Pharmacotherapy of Schizophrenia
 
Adhd in-adults
Adhd in-adultsAdhd in-adults
Adhd in-adults
 
Antipsychotics agents
Antipsychotics agents Antipsychotics agents
Antipsychotics agents
 
Antipsychotic Agents
Antipsychotic AgentsAntipsychotic Agents
Antipsychotic Agents
 

En vedette

Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Brian Piper
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettesBrian Piper
 
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Brian Piper
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Brian Piper
 
Adhd - Drugs vs Nutrition for treatment.
Adhd - Drugs vs Nutrition for treatment.Adhd - Drugs vs Nutrition for treatment.
Adhd - Drugs vs Nutrition for treatment.Mellisa McJunkin
 
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...Louis Cady, MD
 
ADHD And Addiction (Rue, 2001)
ADHD And Addiction (Rue, 2001)ADHD And Addiction (Rue, 2001)
ADHD And Addiction (Rue, 2001)Tom Rue
 
Treating Adult ADHD Online with CBT
Treating Adult ADHD Online with CBTTreating Adult ADHD Online with CBT
Treating Adult ADHD Online with CBTJoan Swart
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IIBrian Piper
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Brian Piper
 
Neuropharmacology: Inhalants
Neuropharmacology: InhalantsNeuropharmacology: Inhalants
Neuropharmacology: InhalantsBrian Piper
 
The adhd brain
The adhd brainThe adhd brain
The adhd brainCMoondog
 
Introductory Psychology: Sleep
Introductory Psychology: SleepIntroductory Psychology: Sleep
Introductory Psychology: SleepBrian Piper
 
Advances in psychological treatments for adult ADHD
Advances in psychological treatments for adult ADHDAdvances in psychological treatments for adult ADHD
Advances in psychological treatments for adult ADHDYasir Hameed
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersBrian Piper
 

En vedette (20)

Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettes
 
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013
 
Adhd - Drugs vs Nutrition for treatment.
Adhd - Drugs vs Nutrition for treatment.Adhd - Drugs vs Nutrition for treatment.
Adhd - Drugs vs Nutrition for treatment.
 
Learning Theory
Learning TheoryLearning Theory
Learning Theory
 
Estudio Milwaukee Study
Estudio Milwaukee StudyEstudio Milwaukee Study
Estudio Milwaukee Study
 
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...
New Concepts in the Epidemiology, Diagnosis and Precision Treatment of ADHD i...
 
General anatomy 19 (b)
General anatomy 19 (b)General anatomy 19 (b)
General anatomy 19 (b)
 
ADHD And Addiction (Rue, 2001)
ADHD And Addiction (Rue, 2001)ADHD And Addiction (Rue, 2001)
ADHD And Addiction (Rue, 2001)
 
Treating Adult ADHD Online with CBT
Treating Adult ADHD Online with CBTTreating Adult ADHD Online with CBT
Treating Adult ADHD Online with CBT
 
Treating Adhd 1
Treating Adhd 1Treating Adhd 1
Treating Adhd 1
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part II
 
New ADHD Medication Rules
New ADHD Medication RulesNew ADHD Medication Rules
New ADHD Medication Rules
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
 
Neuropharmacology: Inhalants
Neuropharmacology: InhalantsNeuropharmacology: Inhalants
Neuropharmacology: Inhalants
 
The adhd brain
The adhd brainThe adhd brain
The adhd brain
 
Introductory Psychology: Sleep
Introductory Psychology: SleepIntroductory Psychology: Sleep
Introductory Psychology: Sleep
 
Advances in psychological treatments for adult ADHD
Advances in psychological treatments for adult ADHDAdvances in psychological treatments for adult ADHD
Advances in psychological treatments for adult ADHD
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disorders
 

Similaire à ADHD Drugs

Neuropharmacology: Catecholamines
Neuropharmacology: CatecholaminesNeuropharmacology: Catecholamines
Neuropharmacology: CatecholaminesBrian Piper
 
ADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsYasir Hameed
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part IIBrian Piper
 
Pediatric Psychopharmacology
Pediatric PsychopharmacologyPediatric Psychopharmacology
Pediatric PsychopharmacologyPallav Pareek
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDBrian Piper
 
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)Sawsan Aboul-Fotouh
 
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intakemothersafe
 
JP_202_ADHDSTIM_FINAL
JP_202_ADHDSTIM_FINALJP_202_ADHDSTIM_FINAL
JP_202_ADHDSTIM_FINALJames Provost
 
Neuropharmacology: Affective Disorders
Neuropharmacology: Affective DisordersNeuropharmacology: Affective Disorders
Neuropharmacology: Affective DisordersBrian Piper
 
Natural Treatments for ADHD - April 11, 2018
Natural Treatments for ADHD - April 11, 2018Natural Treatments for ADHD - April 11, 2018
Natural Treatments for ADHD - April 11, 2018Louis Cady, MD
 
Transition from methylphenidate or amphetamine to atomoxetine in children and...
Transition from methylphenidate or amphetamine to atomoxetine in children and...Transition from methylphenidate or amphetamine to atomoxetine in children and...
Transition from methylphenidate or amphetamine to atomoxetine in children and...hospital higueras
 
05 antidepressants by ravikiran
05 antidepressants by ravikiran 05 antidepressants by ravikiran
05 antidepressants by ravikiran Ravi Kiran
 
Refractory dyslipedimia
Refractory dyslipedimiaRefractory dyslipedimia
Refractory dyslipedimia Mohamed BADR
 
Neuropharmacology: Stimulants
Neuropharmacology: StimulantsNeuropharmacology: Stimulants
Neuropharmacology: StimulantsBrian Piper
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part IIBrian Piper
 
Antidepressants /certified fixed orthodontic courses by Indian dental academy
Antidepressants  /certified fixed orthodontic courses by Indian dental academy Antidepressants  /certified fixed orthodontic courses by Indian dental academy
Antidepressants /certified fixed orthodontic courses by Indian dental academy Indian dental academy
 
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxRECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxashharnomani
 

Similaire à ADHD Drugs (20)

Neuropharmacology: Catecholamines
Neuropharmacology: CatecholaminesNeuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
 
ADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventions
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part II
 
Pediatric Psychopharmacology
Pediatric PsychopharmacologyPediatric Psychopharmacology
Pediatric Psychopharmacology
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSD
 
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)
Novel Fast-Onset Antidepressants (ketamine, Esketamine, Brexanolone)
 
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake
마더리스크라운드 - Dopamine transporter in ADHD & Alcohol intake
 
JP_202_ADHDSTIM_FINAL
JP_202_ADHDSTIM_FINALJP_202_ADHDSTIM_FINAL
JP_202_ADHDSTIM_FINAL
 
11-2022.pptx
11-2022.pptx11-2022.pptx
11-2022.pptx
 
Neuropharmacology: Affective Disorders
Neuropharmacology: Affective DisordersNeuropharmacology: Affective Disorders
Neuropharmacology: Affective Disorders
 
Natural Treatments for ADHD - April 11, 2018
Natural Treatments for ADHD - April 11, 2018Natural Treatments for ADHD - April 11, 2018
Natural Treatments for ADHD - April 11, 2018
 
Transition from methylphenidate or amphetamine to atomoxetine in children and...
Transition from methylphenidate or amphetamine to atomoxetine in children and...Transition from methylphenidate or amphetamine to atomoxetine in children and...
Transition from methylphenidate or amphetamine to atomoxetine in children and...
 
05 antidepressants by ravikiran
05 antidepressants by ravikiran 05 antidepressants by ravikiran
05 antidepressants by ravikiran
 
Refractory dyslipedimia
Refractory dyslipedimiaRefractory dyslipedimia
Refractory dyslipedimia
 
Neuropharmacology: Stimulants
Neuropharmacology: StimulantsNeuropharmacology: Stimulants
Neuropharmacology: Stimulants
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part II
 
Savage
SavageSavage
Savage
 
Antidepressants /certified fixed orthodontic courses by Indian dental academy
Antidepressants  /certified fixed orthodontic courses by Indian dental academy Antidepressants  /certified fixed orthodontic courses by Indian dental academy
Antidepressants /certified fixed orthodontic courses by Indian dental academy
 
Adhd
Adhd Adhd
Adhd
 
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxRECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
 

Plus de Brian Piper

Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part IBrian Piper
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for BipolarBrian Piper
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics IBrian Piper
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNSBrian Piper
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part IBrian Piper
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part IIBrian Piper
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part IBrian Piper
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain InjuryBrian Piper
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromeBrian Piper
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadacheBrian Piper
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseaseBrian Piper
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Brian Piper
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIBrian Piper
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IBrian Piper
 
Pharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseasePharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseaseBrian Piper
 
Migraine and 5-HT
Migraine and 5-HTMigraine and 5-HT
Migraine and 5-HTBrian Piper
 
Adrenergic agonists & antagonists
Adrenergic agonists & antagonistsAdrenergic agonists & antagonists
Adrenergic agonists & antagonistsBrian Piper
 
Neuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaNeuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaBrian Piper
 

Plus de Brian Piper (19)

Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part I
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for Bipolar
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics I
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNS
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part I
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part II
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part I
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & Headache
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's Disease
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part II
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part I
 
Pharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseasePharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons disease
 
Migraine and 5-HT
Migraine and 5-HTMigraine and 5-HT
Migraine and 5-HT
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
Adrenergic agonists & antagonists
Adrenergic agonists & antagonistsAdrenergic agonists & antagonists
Adrenergic agonists & antagonists
 
Neuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaNeuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic ganglia
 

ADHD Drugs

  • 1. Agents For ADHD Brian J. Piper, Ph.D., M.S. piperbj@husson.edu February 12, 2013
  • 2. Goals • Pharmacy students should be: – familiar with ADHD-I, ADHD-HI, and ADHD-C – able to contrast the MOA, AE, and abuse potential of stimulant and non-stimulant pharmacotherapies for ADHD
  • 3. History of ADHD • ≈1910: Minimal Brain Damage: inattentive, distractible, hyper/hypoactive • 1980: Attention Deficit Disorder: normal IQ, poor sustained attention, added to DSM III • 1994: ADD is removed from DSM IV • 2013: “Symptoms present by age” changed from 7 to 12 Taylor (2011). Attention Deficit Hyperactivity Disorder, 3, 69-75.
  • 6. AHDH Epidemiology • Very common in children (6%) & adults (4%) • Substantial regional variability (Maine = 9.6%) • Males (4) > Females (1) • Moderate genetic component in males Visser et al. (2010) MMWR, 59(44), 1439-1433. http://www.cdc.gov/ncbddd/adhd/prevalence.html
  • 7. ADHD Combined: ↓Cortical Volume <- Controls <- ADHD Castellanos et al. (2002). JAMA, 288(14), 1740-1748.
  • 8. Dopamine Transporter (DAT) Dopamine • Neuroanatomy: – Somas: substantia nigra – Axons: striatum • Functions: movement, mood, reward, cognition
  • 9. Dopamine • Neuroanatomy: – Somas: Ventral Tegmental Area (VTA) – Axons: Nucleus Accumbens • Functions: movement, mood, reward, cognition
  • 10. Dopamine • Neuroanatomy: – Somas: Ventral Tegmental Area (VTA) – Axons: Prefrontal Cortex (PFC) • Functions: movement, mood, reward, cognition Modified from Meyer & Quezner (2008). Psychopharmacology.
  • 11. Norepinephrine • Neuroanatomy – somas: Locus Coeruleus – axons: Forebrain+ • Receptors: α1A,1B,1D, α2A,2B,2C, β1, β2, β3 • Function: attention, cardiac Modified from Meyer & Quezner (2008). Psychopharmacology.
  • 12. Amphetamine • History: – synthesized in 1883 – benzedrine in 1933 • Indications: ADHD (age 3+ ), narcolepsy • MOA: – DAT inhibition & reversal – NET inhibition & reversal – VMAT2 inhibition – MAO inhibition (weak)
  • 13. Amphetamine Neurobehavioral Effects ≠ Paradoxical • 14 Boys (age 6-12, IQ = 131) randomized to receive 5 mg/kg dextroamphetamine or placebo • Cognitive battery completed at 30 – 150 min post drug Rapoport, J. et al. (1978). Science, 199, 563-566.
  • 14. Methamphetamine • History: synthesized in 1893 • Indications: ADHD, obesity • Metabolite: amphetamine • MOA: – DAT inhibition & reversal – NET inhibition & reversal – SERT inhibition & reversal – VMAT2 inhibition – MAO inhibition ( ? )
  • 15. Methylphenidate • History: synthesized in 1944 • Adverse Effects: – nervousness – ↓ appetite/weight – ↑blood pressure/heart rate Leandro (& Marguerite) • MOA: Panizzon – DAT/NET inhibition – DA/NE release (moderate) http://www.cesar.umd.edu/cesar/drugs/ritalin.asp
  • 16. Comparison (All Schedule II) • Amphetamine (Adderall): • Methamphetamine (Desoxyn): • Methylphenidate (Ritalin SR):
  • 17. Monitoring the Future: “Amphetamines” = Adderall & Ritalin
  • 18. Recreational Methamphetamine & 11 DAT Depletions [ C]d-methylphenidate Volkow et al. (2001). Journal of Neuroscience, 21(23), 9414-9418.
  • 19. Stimulants & Neurotoxicity • Rats received doses, chosen to produce 2-5X plasma therapeutic levels of: – amphetamine (AMPH) – methamphetamine (METH) – methylphenidate (MPH) • Animals monitored for hyperthermia • Dopamine at 1 week: – MPH = controls – ↓ METH – ↓ AMPH Levi et al. (2012). Neurotoxicology & Teratology, 34, 253-262.
  • 20. Diversion Proof? Lisdexamfetamine Guanfacine Atomoxetine DAT/NET, MOA D-amphetamine NRI prodrug α2A agonist ADHD (>6 yrs), ADHD, ADHD Indications hypertension Scheduled Yes, II No No Abuse potential, Suicidal Warning sudden death No thoughts/ behavior
  • 21. Total estimated number of outpatient prescriptions for ADHD drug market drug products dispensed to the US children (ages 0–17 years) from US retail pharmacies. --------------------------------------------------------------------------------------------------- ↓ -------------------------------------------------------------------------------------------------- ↑ ↑ ↓ Chai G et al. (2012). Pediatrics, 130, 23-31.
  • 22. Treatment for ADHD (DiPiro) • “Multimodal treatment (parent training, family training, classroom interventions, contingency management) is crucial for an overall positive therapeutic outcome.” • Pharmacotherapies – 1st Line: methylphenidate or amphetamine – 2nd Line: atomoxetine or guanafacine or bupropion – 3rd Line: combine above or add tricyclic antidepressant Copheide & Pliszka (2011). In DiPiro’s Pharmacotherapy: A Pathophysiological Approach, p. 1088.
  • 23. Treatment for Hyperkinetic Disorder (European) • 1st Line: Psychoeducation • 2nd Line: methylphenidate • 3rd Line: other stimulant • 4th Line: TCA, nicotine patch Taylor et al. (2004). Eur Child & Adolescent Psychiatry, 13(S1), DOI 10.1007/s00787-004-1002-x
  • 24. Multimodal Treatment Study of Children With ADHD (MTA) • Children (7-10 y.o.) with ADHD-C (N=579) randomized for 14 months to: – Medication Management (MM): methylphenidate (37.7 mg/day), monthly monitoring of adverse effects (parent) – Behavioral Therapy (BT): summer camp (9 hours/day x 5 weeks) + parent training + teaching aid (60 days) – Combined (MM & BT): methylphenidate (30.5 mg/day), monthly monitoring of adverse effects (parent & teacher) – Community Care: treatment as usual in the community (67% pharmacotherapy) MTA Group (1999). Archives of Psychology, 56(12), 1073-1086.
  • 25. Interpretation? • 1) All groups improved relative to baseline. • 2) Behavioral Treatment doesn’t work • 3) Medication Management > Other • 4) Behavioral Treatment = Community Care -------------------------------------------------------------------- MTA Group (1999). Archives of Psychology, 56(12), 1073-1086.

Notes de l'éditeur

  1. Stevens-Johnson syndrome
  2. DSM5 will now note: “Several noticeable inattentive or hyperactive-impulsive symptoms were present by age 12”
  3. Detailed report at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm?s_cid=mm5944a3_wThis notes SES differences (higher rates for parents on Medicaid) but also SES (lower rates for Hispanic).
  4. Differences were retained when potential confounds (group differences in body weight/medication) were included in the statistics.
  5. Midsagital view of rat brain (bottom) and PET of human brain (upper right). VMAT2 is an integral membrane protein that transports monoamines—including dopamine, norepinephrine, serotonin, and histamine—from cellular cytosol into synaptic vesicles
  6. tegmentum is Latin for covering. VTA is found in midbrain or mesencephalon.
  7. Adrenergic receptors in heart increase rate of heart contractility. α1 also has subtypes: α1A, α1B, α1D as does α2 with α2A, 2B, 2C
  8. Amphetamine was first synthesized in 1887 by the Romanian chemist LazărEdeleanu in Berlin, Germany. Benzedrine marketed by Smith Kline &amp; French was originally a non-prescription drug used for bronchodialation for people with asthma. Some individuals used Benzedrine recreationally by cracking the container open and swallowing the paper strip inside, which was covered in Benzedrine.
  9. Word recall was assessed by a word game with lists of 20 words. CPT test involved press a button if a 4 appeared but only if it was preceded by a 6. Interestingly, 12 of 14 children correctly identified the medication day.
  10. Shortly after the first synthesis of amphetamine in 1887, methamphetamine was synthesized from ephedrine 1893 by Japanese chemist Nagai Nagayoshi.
  11. Originally synthesized in 1944 and released in 1948.
  12. General description of the study available here: http://www.bnl.gov/bnlweb/pubaf/pr/2001/bnlpr120101b.htm
  13. Guanfacine is approved as a monotherapy and adjunct for ADHD. For Guanfacine, Intuniv is approved for ADHD but Tenex (same molecule) is approved for hypertension. NRI =Norepinephrine Reuptake Inhibitor. NET takes up both NE and some dopamine.
  14. Note that the individually tailored dose in Combined was less than that in MM.